The importance of long-term efficacy as well as safety and tolerability for cell and gene therapies is amplified as development of these one-time treatments moves from rare monogenic diseases with small numbers of patients into chronic conditions affecting millions of people, according to executives speaking at the Alliance for Regenerative Medicine (ARM)’s annual Cell and Gene Meeting on the Mesa.
Moving Cell And Gene Therapies Into Chronic Conditions Depends On Durability, Safety
Technologies, Trials Designed For Long-Term Efficacy, Safety
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.
